|
|
Post by agedhippie on Sept 7, 2020 21:40:19 GMT -5
How can it take seven years to award a patent? But more to the point, in seven years nothing has come of it. I think it’s been stated here many times, these patents are worthless if they aren’t monetized. Let’s continue to wait and see, or was that rest and grow.i get confused with so many astute and insightful statements from our “CEO”. A lot of patents are taken out for defensive purposes in case you ever have someone come after you. If that happens you want as many patents as possible as with luck there will be patents you can retaliate with. I have four patents to my name, but they are definitely not great. One company I worked for made it really easy for us to file patents and built up a huge arsenal. If you had something was even passingly novel they wanted you to patent it. There were R&D tax credits worked into this somehow as well. |
|
|
|
Post by goyocafe on Sept 7, 2020 21:57:30 GMT -5
How can it take seven years to award a patent? But more to the point, in seven years nothing has come of it. I think it’s been stated here many times, these patents are worthless if they aren’t monetized. Let’s continue to wait and see, or was that rest and grow.i get confused with so many astute and insightful statements from our “CEO”. A lot of patents are taken out for defensive purposes in case you ever have someone come after you. If that happens you want as many patents as possible as with luck there will be patents you can retaliate with. I have four patents to my name, but they are definitely not great. One company I worked for made it really easy for us to file patents and built up a huge arsenal. If you had something was even passingly novel they wanted you to patent it. There were R&D tax credits worked into this somehow as well. ”Defensive” certainly fits the generally passive profile that MannKind has demonstrated over the years. |
|
|
|
Post by neil36 on Sept 16, 2020 9:17:42 GMT -5
From today’s agenda at the International Cannabinoid Derived Pharmaceutical Summit web page: 12.50 pm Cannabinoids Delivered as Novel Solid Dosage Forms – Proof-of-Concept Clinical Data The effectiveness of cannabinoid medicines is negatively impacted by very low bioavailability, highly variable absorption, and erratic time to onset Currently available cannabinoid dosage forms attempt to compensate for some of these deficiencies with high doses that have the potential to produce undesirable side effects Receptor is developing solid dosage forms, both oral and inhaled, that address all of these cannabinoid delivery challenges. Data from 2 initial, proof-of-concept clinical studies will demonstrate the feasibility of this approach Andrea Leone-Bay, Chief Scientific Officer and Founder, Receptor Life Sciences international-cdp.com/whats-on/agenda/day-one/ |
|
